raludotatug deruxtecan + bevacizumab

Raludotatug deruxtecan + bevacizumab is an experimental combination therapy comprising **raludotatug deruxtecan**, a specifically engineered CDH6-directed DXd antibody-drug conjugate (ADC), and **bevacizumab**, a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A). Raludotatug deruxtecan is designed to deliver cytotoxic deruxtecan to CDH6-expressing tumor cells, inducing cell death primarily in ovarian, fallopian tube, and primary peritoneal cancers resistant to platinum chemotherapy. Bevacizumab inhibits angiogenesis by neutralizing VEGF-A, thereby suppressing new blood vessel formation to the tumor. This combination is under clinical investigation for efficacy and safety in platinum-resistant gynecologic cancers, especially those expressing CDH6 and with prior exposure to bevacizumab. The two drugs act via distinct, complementary mechanisms: targeting tumor cell survival and the supporting tumor microvasculature, respectively[1][2][4][5][6][7].

Other names

raludotatug deruxtecan and bevacizumab